88 related articles for article (PubMed ID: 7792733)
1. Effects of two different doses of hirudin on APTT, determined with eight different reagents.
Monreal M; Monreal L; Ruiz de Gopegui R; Espada Y; Angles AM; Monasterio J
Thromb Haemost; 1995 Feb; 73(2):219-22. PubMed ID: 7792733
[TBL] [Abstract][Full Text] [Related]
2. Effects of hirudin on activated partial thromboplastin time determined with ten different reagents.
Tripodi A; Chantarangkul V; Arbini AA; Moia M; Mannucci PM
Thromb Haemost; 1993 Aug; 70(2):286-8. PubMed ID: 8236136
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamic and safety results of PEG-Hirudin in healthy volunteers.
Esslinger HU; Haas S; Maurer R; Lassmann A; Dübbers K; Müller-Peltzer H
Thromb Haemost; 1997 May; 77(5):911-9. PubMed ID: 9184402
[TBL] [Abstract][Full Text] [Related]
4. The comparative effects of recombinant hirudin (CGP 39393) and standard heparin on thrombus growth in rabbits.
Agnelli G; Pascucci C; Cosmi B; Nenci GG
Thromb Haemost; 1990 Apr; 63(2):204-7. PubMed ID: 2363121
[TBL] [Abstract][Full Text] [Related]
5. Experimental studies on a recombinant hirudin, CGP 39393.
Gray E; Watton J; Cesmeli S; Barrowcliffe TW; Thomas DP
Thromb Haemost; 1991 Apr; 65(4):355-9. PubMed ID: 2057916
[TBL] [Abstract][Full Text] [Related]
6. Monitoring anticoagulant therapy by activated partial thromboplastin time: hirudin assessment. An evaluation of native blood and plasma assays.
Nurmohamed MT; Berckmans RJ; Morriën-Salomons WM; Berends F; Hommes DW; Rijnierse JJ; Sturk A
Thromb Haemost; 1994 Nov; 72(5):685-92. PubMed ID: 7900075
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of coagulometric assays in the assessment of protein C anticoagulant activity; variable sensitivity of commercial APTT reagents to the cofactor effect of protein S.
D'Angelo SV; Gilardoni F; D'Angelo A
Thromb Haemost; 1989 Nov; 62(3):861-7. PubMed ID: 2531939
[TBL] [Abstract][Full Text] [Related]
8. [The pharmacokinetics and pharmacodynamics of recombinant hirudin-2 nasal spray].
Zhang YJ; Zhang Q; Hou JL; Wang XL; Chen MX
Yao Xue Xue Bao; 2006 Mar; 41(3):268-71. PubMed ID: 16759001
[TBL] [Abstract][Full Text] [Related]
9. Monitoring heparin therapy using activated partial thromboplastin time--results of a multicenter trial establishing the therapeutic range for SILIMAT, a reagent with high sensitivity to heparin.
Toulon P; Boutière B; Horellou MH; Trzeciak MC; Samama MM
Thromb Haemost; 1998 Jul; 80(1):104-8. PubMed ID: 9684794
[TBL] [Abstract][Full Text] [Related]
10. The influence of infusions of 1-desamino-8-D-arginine vasopressin (DDAVP) in vivo on the anticoagulant effect of recombinant hirudin (CGP39393) in vitro.
Ibbotson SH; Grant PJ; Kerry R; Findlay VS; Prentice CR
Thromb Haemost; 1991 Jan; 65(1):64-6. PubMed ID: 1902596
[TBL] [Abstract][Full Text] [Related]
11. Biological relevance of anti-recombinant hirudin antibodies--results from in vitro and in vivo studies.
Liebe V; Brückmann M; Fischer KG; Haase KK; Borggrefe M; Huhle G
Semin Thromb Hemost; 2002 Oct; 28(5):483-90. PubMed ID: 12420244
[TBL] [Abstract][Full Text] [Related]
12. Biologic effects of recombinant hirudin (CGP 39393) in human volunteers. European Hirudin in Thrombosis Group.
Verstraete M; Nurmohamed M; Kienast J; Siebeck M; Silling-Engelhardt G; Büller H; Hoet B; Bichler J; Close P
J Am Coll Cardiol; 1993 Oct; 22(4):1080-8. PubMed ID: 8409044
[TBL] [Abstract][Full Text] [Related]
13. The monitoring of heparin administration by screening tests in experimental dogs.
Mischke R; Jacobs C
Res Vet Sci; 2001 Apr; 70(2):101-8. PubMed ID: 11356088
[TBL] [Abstract][Full Text] [Related]
14. A comparison of the sensitivity of APTT reagents to the effects of enoxaparin, a low-molecular weight heparin.
Ip BK; Thomson AR; Moriarty HT
Pathology; 2001 Aug; 33(3):347-52. PubMed ID: 11523938
[TBL] [Abstract][Full Text] [Related]
15. Markers of hemostatic system activation during thromboprophylaxis with recombinant hirudin in total hip replacement.
Cofrancesco E; Cortellaro M; Leonardi P; Corradi A; Ravasi F; Bertocchi F
Thromb Haemost; 1996 Mar; 75(3):407-11. PubMed ID: 8701398
[TBL] [Abstract][Full Text] [Related]
16. The effect of aprotinin on the response of the activated partial thromboplastin time (APTT) to heparin.
Francis JL; Howard C
Blood Coagul Fibrinolysis; 1993 Feb; 4(1):35-40. PubMed ID: 7681330
[TBL] [Abstract][Full Text] [Related]
17. [Effect of reagent batch on activated partial thromboplastin time in canine plasma and use of the ratio system for standardization].
Mischke R
Berl Munch Tierarztl Wochenschr; 2002; 115(5-6):225-9. PubMed ID: 12058600
[TBL] [Abstract][Full Text] [Related]
18. The therapeutic range for heparin therapy: relationship between six activated partial thromboplastin time reagents and two heparin assays.
Kitchen S; Preston FE
Thromb Haemost; 1996 May; 75(5):734-9. PubMed ID: 8725715
[TBL] [Abstract][Full Text] [Related]
19. A recombinant hirudin (IK-HIR02) in healthy volunteers. I. Effects on coagulation parameters and bleeding time.
Schenk JF; Glusa E; Radziwon P; Butti A; Markwardt F; Breddin HK
Haemostasis; 1996; 26(3):140-9. PubMed ID: 8738588
[TBL] [Abstract][Full Text] [Related]
20. [Comparison of factor VIII:C and factor IX sensitivity of different commercial APTT reagents for canine plasma].
Mischke R
Berl Munch Tierarztl Wochenschr; 1999; 112(10-11):394-9. PubMed ID: 10598358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
